Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Secures Arbitration Victory for GPC Biotech

November 6, 2007

WASHINGTON, DC, November 6, 2007 — Covington & Burling LLP has won a favorable arbitration ruling for GPC Biotech AG in its dispute with Spectrum Pharmaceuticals, Inc. Yesterday, a three-arbitrator panel of the American Arbitration Association unanimously rejected all of Spectrum’s claims against GPC Biotech under their co-development and license agreement for satraplatin, a compound that has shown promise in the treatment of various cancers. GPC Biotech, is a publicly traded biopharmaceutical company headquartered in Germany.

The Covington team was led by partners Tony Herman and Ed Rippey, with assistance from Ben Razi, Emily Porter, and Ted Metzler. All are based in the firm’s Washington office.

For more information on the ruling, please visit GPC Biotech’s website.

Share this article: